Clinical trial

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine…

NCT00002124 · Pharmacia and Upjohn, Industry · Completed

Key facts

NCT number NCT00002124
Title A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
Official title A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
Lead sponsor Pharmacia and Upjohn, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Delavirdine mesylate, Lamivudine, Zidovudine
Enrollment 1,250
First posted Aug 31, 2001
Last update posted Jun 24, 2005
Countries Puerto Rico, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies